Merkel Cell Carcinoma Therapeutic Update

Area of Science:

• Oncology
• Dermatology
• Immunology

Background:

• Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine skin cancer.
• Early-stage MCC is treatable with surgery and radiotherapy (RT).
• Sentinel lymph node biopsy (SLNB) is crucial for staging MCC.

Purpose of the Study:

• To review current treatment strategies for MCC.
• To explore the potential of immunotherapy for advanced MCC.
• To discuss the role of Merkel cell polyomavirus (MCV) status in treatment response and future research.

Main Methods:

• Review of recent studies on MCC treatment, including surgery, RT, chemotherapy, and immunotherapy.
• Analysis of high-throughput sequencing data differentiating MCV-positive and MCV-negative tumors.
• Discussion of clinical trial endpoints and precision medicine approaches.

Main Results:

• Adjuvant RT may improve locoregional control in some MCC cases.
• Immunotherapy targeting PD-1/PD-L1 checkpoints shows promise for advanced MCC.
• MCV status correlates with tumor mutational burden, impacting potential treatment responses.

Conclusions:

• Advanced MCC treatment remains challenging, with chemotherapy responses often not durable.
• Immunotherapy offers a promising avenue for advanced MCC.
• Stratifying MCC patients by viral status is essential for future clinical trials and precision medicine.